MACO - PHARMA BENELUX
MACO - PHARMA BENELUX has been active since 1992 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.05M and a net result of €73k. Equity remains stable across the filed fiscal years (±0% per year). The computed 12-month bankruptcy probability is 0.3% (very low).
| Equity | €3.05M |
| Net result | €73k |
| Staff (FTE) | 5 |
| Active | 33 yrs |
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Deposit | full schema | unclassified schema | unclassified schema |
| Revenue | €3.68M | €3.64M | €3.81M |
| EBITDA | €109k | €169k | €88k |
| Net profit | €73k | €620k | €50k |
| Cash flow | €78k | €628k | €58k |
| Staff costs | €580k | €588k | €483k |
| Income taxes | €33k | €28k | €26k |
| Dividends | €73k | €620k | €50k |
| Total assets | €4.19M | €4.45M | €3.93M |
| Equity | €3.05M | €3.05M | €3.05M |
| Debt | €1.14M | €1.40M | €788k |
| of which ≤ 1y | €1.14M | €1.40M | €788k |
| of which > 1y | - | - | - |
| Working capital | €341k | €330k | €415k |
| Employees (FTE) | 5.0 | 5.0 | 5.0 |
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Current ratio | 1.30 | 1.24 | 1.53 |
| Quick ratio | 1.28 | 1.22 | 1.49 |
| Working capital ratio | 8.1% | 7.4% | 10.5% |
| Solvency | 72.8% | 68.6% | 77.6% |
| Debt / equity | 0.37 | 0.46 | 0.26 |
| Long-term debt ratio | - | - | - |
| Interest coverage | 9.01 | 456.16 | 2204.35 |
| Gross margin | 23.6% | 27.0% | 24.2% |
| Net margin | 2.0% | 17.0% | 1.3% |
| ROA | 1.7% | 13.9% | 1.3% |
| ROE | 2.4% | 20.3% | 1.6% |
| EBITDA margin | 3.0% | 4.6% | 2.3% |
| Days sales outstanding | 84d | 81d | 78d |
| Days payable outstanding | 106d | 74d | 63d |
| Inventory turnover | 138.92 | 114.54 | 107.71 |
| Days inventory (DSI) | 3d | 3d | 3d |
Full annual accounts (26 line items)
| Line item | Code | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet, Assets | ||||
| TOTAL ASSETS | 20/58 | €4.19M | €4.45M | €3.93M |
| Fixed assets | 21/28 | €2.71M | €2.72M | €2.73M |
| Formation expenses | 20 | €0 | €0 | €0 |
| Tangible fixed assets | 22/27 | €6k | €17k | €23k |
| Financial fixed assets | 28 | €2.70M | €2.70M | €2.70M |
| Current assets | 29/58 | €1.48M | €1.73M | €1.20M |
| Stocks & contracts in progress | 3 | €20k | €23k | €27k |
| Amounts receivable within one year | 40/41 | €1.44M | €1.64M | €1.10M |
| Cash & bank | 54/58 | €22k | €64k | €77k |
| Balance sheet, Equity & liabilities | ||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €4.19M | €4.45M | €3.93M |
| Equity | 10/15 | €3.05M | €3.05M | €3.05M |
| Contributions / capital | 10/11 | €62k | €62k | €62k |
| Reserves | 13 | €6k | €6k | €6k |
| Accumulated profits (losses) | 14 | €2.98M | €2.98M | €2.98M |
| Provisions & deferred taxes | 16 | - | - | €91k |
| Amounts payable | 17/49 | €1.14M | €1.40M | €788k |
| Amounts payable within one year | 42/48 | €1.14M | €1.40M | €788k |
| Trade debts payable within one year | 44 | €816k | €543k | €499k |
| Income statement | ||||
| Turnover | 70 | €3.68M | €3.64M | €3.81M |
| Operating result | 9901 | €104k | €161k | €80k |
| Financial income | 75 | €14k | €570k | €6k |
| Financial charges | 65 | €12k | €12k | €11k |
| Result before taxes | 9903 | €106k | €648k | €75k |
| Income taxes | 67/77 | €33k | €28k | €26k |
| Net result for the period | 9904 | €73k | €620k | €50k |
| Result to be appropriated | 9905 | €73k | €620k | €50k |
| NACE primary | Manufacture of basic pharmaceutical products and pharmaceutical preparations(21201) |
| Legal form | Private limited company(610) |
| Incorporation | 28-09-1992 |
| Status | Active |
| Postal code | 7700 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 54435G0698/02A000 | Wallonia | 1,286 m² | 1 · 1,233 m² | - |
We know of 12 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
19-03-2025 1 director appointed, 1 resigning
- Gaëtan Roy, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": "B01030",
"name": "Ga\u00EBtan Roy",
"address": null,
"birth_date": null,
"profession": "r\u00E9viseur d\u0027entreprises",
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": {
"kbo": null,
"name": "SRL PwC Reviseurs d\u0027Entreprises",
"address": "831 Diegem, Culliganlaan 5",
"country": "BE",
"legal_form": "SRL"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u0027Actionnaire unique, conform\u00E9ment \u00E0 la propositon de l\u0027organe d\u0027administration de la Soci\u00E9t\u00E9, d\u00E9cide de renouveler le mandat de la SRL PwC Reviseurs d\u0027Entreprises, ayant son si\u00E8ge social \u00E0 831 Diegem, Culliganlaan 5, comme commissaire pour un terme de trois ans.",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "3"
},
"rep_rotation_new_rep": "Ga\u00EBtan Roy",
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Ga\u00EBtan Roy",
"address": null,
"birth_date": null,
"profession": "r\u00E9viseur d\u0027entreprises",
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 3:60 du Code des soci\u00E9t\u00E9s et des associations, cette soct\u00E9\u00E9 d\u00E9signe comme repr\u00E9sentant Monsieur Ga\u00EBtan Roy SRL (B01030), r\u00E9viseur d\u0027entreprises, et le charge de l\u0027exercice de ce mandat, avec comme repr\u00E9sentant permanent Ga\u00EBtan Roy, \u00E9galement r\u00E9viseur d\u0027entreprises.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "mandate_termination_de_plein_droit",
"role": null,
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Le mandat viendra \u00E0 \u00E9ch\u00E9ance \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires appel\u00E9e \u00E0 statuer sur les comptes annuels de l\u0027exercice social qui sera cl\u00F4tur\u00E9 le 31 d\u00E9cembre 2026.",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2026"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-03-19",
"filing_date": "2025-03-11",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2024-05-17",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0448.280.649",
"name_full": "MACO-PHARMA Benelux",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "IMPULSO Fiduciaire S.R.L.",
"person_name": null,
"org_rep_person_name": "A.Chavanne",
"person_role_at_subject": null
},
"co_filed_documents": [
"Proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire du 17/05/2024"
],
"corrected_publication_numac": null
}| Legal nameFR | MACO - PHARMA BENELUX |